We’ve all read the stories: the success of Novo Nordisk’s diabetes-turned-weight-loss drugs driving a 53 percent share increase over 2023; how the 100-year-old pharmaceutical company grew to be bigger than its next 10 domestic peers; Novo Nordisk’s place as Denmark’s biggest taxpayer, turning what would have been a recession into economic growth; the 10,000-employee-party in a field in Roskilde – the site of one of Europe’s most famous festivals – to celebrate. And the company doesn’t just perform well financially: it regularly tops lists of the best places . . .
Log in FOR FREE to access this content
Log in or create your free My IR – Essentials account to:
- Access 50+ deep dives and best practice reports
- View 100+ news analyses and our exclusive CFO series
- Instantly benchmark your IR program with our new tool
- Save favorites and get tailored content delivered to your dashboard
- 10% off all IR forums!
Join now to make a real impact in your organization.
